Direct Compression Window With High-Speed Rotary Press Feed Frames

Calcium Aspartate Pharma Grade API as supplied for solid-dosage manufacturing typically presents a fine particle fraction and moderate bulk density. When formulated by direct compression, the API is blended with microcrystalline cellulose NF (PH-102) and partially pregelatinized starch NF in a bin blender operated at 10–15 rpm for 15–20 min. The lack of granulation fluid keeps the API surface dry, reducing hydrate conversion risk. Blend uniformity is verified per USP <905>; acceptance criteria are set at 90.0–110.0% label claim with RSD not more than 5.0%. On a 16-station rotary tablet press, compression force is maintained between 8 kN and 14 kN to achieve tablet hardness of 60–90 N without capping. Precompression force at 2–4 kN reduces entrapped air. Croscarmellose sodium at 2.0% w/w is used as disintegrant; magnesium stearate at 0.5% w/w is introduced with final blending limited to 3 min to avoid hydrophobic coating of the Calcium Aspartate particles. Dissolution testing per USP <711> using 0.1 N hydrochloric acid at 50 rpm basket speed is run to a target of not less than 80% release within 30 min for an immediate-release tablet. The principal processing limit is airborne fines; if the fraction passing 100 mesh exceeds 30%, feed frame paddle speed should be capped at 30–40 rpm to reduce die filling noise and weight variation. Tablet friability per USP <1216> is controlled below 0.8%. Moisture is measured by USP <921> Karl Fischer titration; a moisture content above 2.0% w/w indicates that the blend should be dried or reconditioned at 40°C and less than 30% RH before compression.

Capsule filling of Calcium Aspartate presents a different set of constraints from tableting because plug formation is governed by the powder’s resistance to densification under low compression. If the tapped density of the blend per USP <616> remains below 0.60 g/cm³, weight variation on a 7,000–10,000 capsule/hour machine may exceed the USP <905> limit of 90.0–110.0%. To mitigate this, the API is blended with spray-dried lactose monohydrate and a small quantity of colloidal silicon dioxide at 0.2–0.5% w/w. Pre-gelatinized starch NF at 5–10% w/w acts as a low-moisture filler. The final blend is passed through a 30-mesh screen. On an automatic capsule filling line with a disk compression station, the plug compression thickness is adjusted to 12–15 mm depending on powder bulk density and target fill weight. Additives that increase moisture sensitivity, such as croscarmellose sodium, are limited to 2.0% w/w because the shell may absorb moisture from the fill and become brittle. Capsule shells are checked for brittleness by visual inspection after 24 h storage at 40°C / 75% RH. For a 300 mg Calcium Aspartate fill weight, size 0 or 00 hard gelatin capsules are common; hydroxypropyl methylcellulose capsules are accepted if residual moisture is held below 7.0% w/w. Dissolution of filled capsules is run per USP <711> with sinkers, and the specification is aligned with immediate-release criteria. Process audits monitor capsule moisture by USP <921> and shell puncture force after packaging. A compatibility issue appears when liquid-filled hard capsules are attempted with Calcium Aspartate in polyethylene glycol 400; published data for this specific configuration is limited, and gelatin softening may occur above 25% water in the fill. Such formulations require preformulation studies for fill migration and shell compatibility.

Does Aqueous High-Shear Granulation Shift the Chelate Stability of Calcium Aspartate?

Calcium Aspartate is a chelate formed from calcium ion and aspartate anion, and its stability in aqueous granulation depends on pH and thermal history. In a high-shear mixer, the dry blend containing API, lactose monohydrate, and povidone K30 is premixed at impeller speed 200 rpm; purified water is added at a spray rate of 50–80 g/min per kg dry mix. The impeller speed is then raised to 300–500 rpm and the chopper to 1,500–2,000 rpm until wet mass torque reaches a defined endpoint. Granule moisture is held between 8% and 12% w/w by loss on drying per USP <731>. Fluid-bed drying follows at inlet air temperature 55–65°C, and product temperature is kept below 45°C to avoid disrupting the aspartate complex. If the dried granules are milled with a 1.0 mm screen, the fraction below 150 µm should not exceed 25% because fines segregate during compaction and create weight variation. Published data for the aqueous granulation behavior of Calcium Aspartate is limited compared with calcium carbonate or calcium citrate; therefore, a laboratory-scale compatibility study using differential scanning calorimetry and forced degradation at 60°C / 75% RH for 7 days is recommended before locking the binder level. The granule blend is compressed with compaction force 10–16 kN; tablet hardness is measured per USP <1217>. Dissolution verification per USP <711> in 900 mL of 0.1 N HCl at 75 rpm should show no slower release than the direct compression comparator. Because the granulation step introduces water, the final moisture specification per USP <921> is set at not more than 2.5% w/w to avoid microbial growth and soft tablets.

Roller compaction is preferred for Calcium Aspartate formulations that will be filled into sachets or reconstituted as oral granules because no aqueous binder is introduced. The premix is blended with microcrystalline cellulose NF, crospovidone, and magnesium stearate; it is fed to a roller compactor with roll surface pressure set between 4 kN/cm and 10 kN/cm, gap 2–4 mm, and roll speed 3–8 rpm. Ribbon density is measured by pycnometry or simple geometric weight; a target ribbon density of 0.90–1.10 g/cm³ provides a balance between tablet strength and downstream rework. If ribbon hardness is too high, disintegration in oral suspension may exceed 15 min per USP <701>. The milled granules are screened to 425–710 µm after milling through a 1.25 mm perforated screen. Fines below 150 µm are reintroduced to the compactor at no more than 20% of the feed rate; higher rework ratios increase the fraction of work-hardened particles and reduce granule porosity. Content uniformity is confirmed after final blending with a thief sampling plan based on USP <905>. For sachet packaging, granule moisture is held below 1.5% w/w by USP <921> and the fill volume is verified gravimetrically because the material is marketed by mass, not volume. A desiccant is required when the sachet film has water vapor transmission rate above 0.5 g/m²/day at 38°C / 90% RH. This dry granulation route is less suited to very low-dose Calcium Aspartate products where API content is below 5% w/w, because drug distribution can be lost in the excipient mass during compaction; direct blending into a trituration or geometric dilution is then required.

Terminal Steam Sterilization and Container Closure Limits for Injectable Calcium Aspartate

An injectable solution of Calcium Aspartate is prepared by dissolving the API in water for injection at 40–50°C under nitrogen purging to minimize dissolved carbon dioxide. The solution pH is adjusted between 5.5 and 7.0 with dilute hydrochloric acid or sodium hydroxide; above 7.5, atmospheric carbon dioxide can generate calcium carbonate particulates, and below 4.0, the aspartate anion becomes progressively protonated, altering chelation equilibrium. The bulk solution is filtered through a 0.22 µm membrane and filled into Type I borosilicate glass vials per USP <660>. Terminal sterilization is performed in a saturated-steam autoclave at 121°C for a dwell of 15 min, or an equivalent cycle delivering F₀ not less than 15. Because Calcium Aspartate is sensitive to long thermal exposure at high pH, cycle development should include a post-sterilization assay and pH check; solution discoloration above a defined yellowness limit is cause for rejection. Endotoxin content is controlled in the API and excipients; the final solution is tested by USP <85> or Ph. Eur. 2.6.14 to a limit of 0.25 EU/mL for a typical parenteral infusion. Particulate matter is checked per USP <788>; containers must meet ≤ 25 particles/mL for particles ≥ 10 µm and ≤ 3 particles/mL for particles ≥ 25 µm. Sterility testing per USP <71> remains the release test. The main incompatibility is phosphate-containing diluents; if the injection is mixed with phosphate buffer, calcium phosphate precipitation occurs readily above a calcium concentration of 20 mmol/L. Therefore, the pharmaceutical development report must specify compatible diluents, typically 0.9% sodium chloride or 5% dextrose. This route is used for small-volume parenterals rather than large-volume parenterals unless the calcium concentration is kept low enough to avoid tonicity excursions; osmolality is measured per USP <785> and adjusted with sodium chloride.

A lyophilised injection form of Calcium Aspartate removes the thermal stress associated with terminal sterilization but introduces freeze-drying parameters that must be mapped for each vial size. The solution is prepared at 10–50 mg/mL Calcium Aspartate in water for injection, with mannitol or glycine added as bulking agent at 2–5% w/v. The filling volume is adjusted to 5 mL or 10 mL per 20 mL vial, and the rubber stopper is selected for low moisture vapor transmission. Freeze-drying is run by first freezing at shelf temperature -40°C for 2 h; annealing at -10°C for 1–2 h can improve ice crystal structure. Primary drying is typically conducted at shelf temperature -25°C and chamber pressure 10–15 Pa until the product temperature remains below the collapse temperature determined by freeze-dry microscopy. Secondary drying is programmed at 35–40°C for 4–6 h to bring residual moisture below 1.0% w/w per USP <921>. The lyophilized cake is checked for appearance, reconstitution time, and pH shift; a collapsed or shrunken cake indicates that the primary drying shelf temperature was set too high relative to the formulation’s collapse temperature. Reconstitution with sterile water for injection should yield a clear solution within 3 min with no visible particles when tested per USP <790>. Endotoxin and sterility release follow the same USP <85> and USP <71> criteria as terminal-sterilized injectables. This freeze-dried route requires geofenced shipment controls if the product is stored at 2–8°C; if stability studies support storage below 25°C, the label may omit cold-chain language, but the lyophilization cycle cannot be shortened without increasing residual moisture above 1.0%.

When Calcium Aspartate Granules Are Filled into Low-Headspace Stick Packs

Calcium Aspartate granules intended for oral solution or suspension in stick packs are processed under humidity-controlled rooms with dew point below 10°C. The dry granulation route described earlier yields granules, but the finished granule must still pass through a 425 µm sieve and retain not more than 10% fines below 150 µm; otherwise, dust generation during vertical form-fill-seal packaging causes fill weight fluctuation and visual defects at the seal area. On a stick pack machine, the film is typically a polyethylene terephthalate/aluminum foil/polyethylene laminate with oxygen transmission rate below 0.5 cm³/m²/day and moisture vapor transmission rate below 0.3 g/m²/day at 38°C / 90% RH. The filling line operates with an auger dosator or volumetric cup system; for a target fill of 1.0 g, weight variation is monitored to ± 5.0% using in-line checkweighers. Residual oxygen in the headspace is purged with nitrogen to below 3.0% v/v for moisture-sensitive grades. The final packaged granule is tested for absent agglomeration after 24 h at 40°C / 75% RH. Because Calcium Aspartate in a dry granule can still exchange moisture through film seals, a desiccant is not always required if seal integrity is confirmed by dye penetration per ASTM F1929-15 and the film is impermeable to water vapor. Dissolution of the reconstituted granules is verified after adding one stick pack to 200 mL of water at 25°C; a clear to slightly opalescent dispersion is expected. The product is not designed as an effervescent system; if citric acid and sodium bicarbonate are added, aspartate ionization in the acid-base environment changes the dissolution profile and effervescent tablet logic does not apply directly. Process validation includes a three-batch fill weight uniformity study under normal operating speed of 120–180 packs/min.